Beauty Care-Cosmetic Procedures, Dermatology / 13.01.2026
What Are the Best Products for Hydrated, Glowing Skin From Head to Toe?
[caption id="attachment_71993" align="aligncenter" width="500"]
Photo by RF._.studio[/caption]
Glowing skin is not only about your face. When your body is hydrated and smooth, everything looks healthier, from shoulders to shins. The best head to toe routine is simple and repeatable, with products that support texture, moisture, and tone. Many body products lean hard on fragrance and a slippery feel, but JLO Beauty puts more emphasis on skincare style ingredients and targeted formulas that treat the body with the same serious approach people expect for the face. If you want a streamlined starting point, it helps to look for body care essentials that cover three jobs: gentle resurfacing, deep moisture, and focused treatment for areas that need extra help.
Photo by RF._.studio[/caption]
Glowing skin is not only about your face. When your body is hydrated and smooth, everything looks healthier, from shoulders to shins. The best head to toe routine is simple and repeatable, with products that support texture, moisture, and tone. Many body products lean hard on fragrance and a slippery feel, but JLO Beauty puts more emphasis on skincare style ingredients and targeted formulas that treat the body with the same serious approach people expect for the face. If you want a streamlined starting point, it helps to look for body care essentials that cover three jobs: gentle resurfacing, deep moisture, and focused treatment for areas that need extra help.
Dr. Thorne[/caption]
Sally Thorne RN, PhD, FAAN, FCAHS, FCAN, CM
Professor Emeritus, School of Nursing
Co-Principal Investigator with :
[caption id="attachment_71969" align="alignleft" width="133"]
Dr. Pesut[/caption]
Dr. Barbara Pesut PhD, RN
Professor in the School of Nursing
Principal Research Chair in Palliative and End of Life Care
University of British Columbia
MedicalResearch.com: What is the background for this study?
Response: Medical assistance in dying (MAiD) was legalized in Canada in June of 2016 for Canadians who were facing a reasonably foreseeable natural death and met an explicit set of eligibility criteria as determined by qualified health care providers (physicians or nurse practitioners). In 2021, the legislation was extended to include the possibility of MAiD for persons who were suffering from a ‘grievous and irremediable’ medical condition but for whom natural death was not immediately foreseeable. As assisted dying represented a significant change in available options for Canadians with terminal or chronic conditions, requiring significant practice adaptations and including numerous legal, social, ethical, moral implications, the health research community has been working in consultation with clinicians, service providers and governments to generate knowledge that ensures safe, ethical and equitable practice in this regard.
Dr. Chunmiao Zheng[/caption]
Chunmiao Zheng, PhD
AGU Fellow, Chair Professor
Hydrologic Science
Eastern Institute of Technology
Ningbo, China
MedicalResearch.com: What is the background for this study?
Response: Per- and polyfluoroalkyl substances (PFAS) are a class of artificially synthesized chemicals widely used in industrial production and consumer goods manufacturing. These substances are persistent in the environment, can accumulate through the food chain, and enter the human body and build up over time, posing a potential threat to health. As an important component of the global diet, marine fish may serve as a major source of PFAS intake for humans. However, the contribution of marine fish as a source of PFAS exposure and the associated health risks still lack systematic assessment on a global scale.
Samson Nivins PhD
Postdoctoral Researcher, specializing in Perinatal and Pediatric Neurology
[caption id="attachment_71834" align="alignleft" width="92"]
Dr. Stone[/caption]
Co-author Meredith Stone, PhD
Assistant Director for Cell Therapy Translation
in Dr. Davila’s lab at Roswell Park - presenting author
MedicalResearch.com: What is the background for this study?
Response: While CD19-targeted CAR T cell therapy has garnered clinical success and FDA approval for the treatment of large B cell lymphoma, approximately half of patients suffer from primary resistance or relapse. Increasing evidence suggests that resistance mechanisms are supported by the tumor microenvironment (TME). Cytokines secreted by CAR T cells can remodel the TME, determining the phenotype and function of other immune cells.